DE60032910D1 - Mittel zum nachweis und zur behandlung von krankheiten die in verbindung stehen mit fgfr3 - Google Patents

Mittel zum nachweis und zur behandlung von krankheiten die in verbindung stehen mit fgfr3

Info

Publication number
DE60032910D1
DE60032910D1 DE60032910T DE60032910T DE60032910D1 DE 60032910 D1 DE60032910 D1 DE 60032910D1 DE 60032910 T DE60032910 T DE 60032910T DE 60032910 T DE60032910 T DE 60032910T DE 60032910 D1 DE60032910 D1 DE 60032910D1
Authority
DE
Germany
Prior art keywords
fgfr3
detection
treatment
medium
diseases related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60032910T
Other languages
English (en)
Other versions
DE60032910T3 (de
DE60032910T2 (de
Inventor
David Cappellen
Dominique Chopin
Francois Radvanyi
David Ricol
Jean-Paul Thiery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Curie
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22455232&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60032910(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Curie filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE60032910D1 publication Critical patent/DE60032910D1/de
Publication of DE60032910T2 publication Critical patent/DE60032910T2/de
Publication of DE60032910T3 publication Critical patent/DE60032910T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60032910T 1999-05-05 2000-05-04 Mittel zum nachweis und zur behandlung von krankheiten die in verbindung stehen mit fgfr3 Expired - Lifetime DE60032910T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13270599P 1999-05-05 1999-05-05
US132705P 1999-05-05
PCT/EP2000/004591 WO2000068424A2 (en) 1999-05-05 2000-05-04 Means for detecting and treating pathologies linked to fgfr3

Publications (3)

Publication Number Publication Date
DE60032910D1 true DE60032910D1 (de) 2007-02-22
DE60032910T2 DE60032910T2 (de) 2007-10-25
DE60032910T3 DE60032910T3 (de) 2010-07-29

Family

ID=22455232

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032910T Expired - Lifetime DE60032910T3 (de) 1999-05-05 2000-05-04 Mittel zum nachweis und zur behandlung von krankheiten die in verbindung stehen mit fgfr3

Country Status (6)

Country Link
EP (1) EP1208231B2 (de)
AU (1) AU5214500A (de)
CA (1) CA2372990C (de)
DE (1) DE60032910T3 (de)
ES (1) ES2280218T5 (de)
WO (1) WO2000068424A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072154A1 (en) * 2000-12-22 2004-04-15 Morris David W. Novel compositions and methods for cancer
EP1423428B2 (de) 2001-06-20 2012-11-14 Fibron Ltd. Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
ES2330634T3 (es) * 2003-03-26 2009-12-14 Progenika Biopharma, S.A. Metodo in vitro para detectar carcinoma transicional de vejiga.
EP1659175A1 (de) * 2004-11-18 2006-05-24 Institut Curie Veränderungen in seborrheischen Keratosen und deren Verwendungen
EP1992344A1 (de) * 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
EP2313435A4 (de) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc An den fibroblastenwachstumsfaktorrezeptor 3 (fgfr3) bindende proteine
WO2013088191A1 (en) * 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
US9133328B2 (en) 2011-12-12 2015-09-15 Sa Des Eaux Minerales D'evian Saeme Plastic compositions and containers made thereof
WO2015035415A1 (en) 2013-09-09 2015-03-12 Nantomics, Llc Method of detecting suceptibility to breast cancer through mutations in the fgfr3 and tp53 genes
PL3122358T3 (pl) 2014-03-26 2021-06-14 Astex Therapeutics Ltd. Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN116323666A (zh) 2020-08-21 2023-06-23 建新公司 Fgfr3抗体和使用方法

Also Published As

Publication number Publication date
CA2372990A1 (en) 2000-11-16
DE60032910T3 (de) 2010-07-29
DE60032910T2 (de) 2007-10-25
EP1208231B1 (de) 2007-01-10
WO2000068424A2 (en) 2000-11-16
ES2280218T3 (es) 2007-09-16
AU5214500A (en) 2000-11-21
ES2280218T5 (es) 2010-05-14
CA2372990C (en) 2007-06-19
EP1208231A2 (de) 2002-05-29
EP1208231B2 (de) 2009-12-30
WO2000068424A3 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69930410D1 (de) Infrarotabbildung zum nachweis von bestandteilen in körperpflegeprodukten
ATE260652T1 (de) Arzneimittel und verfahren zur behandlung von aufmerksamkeitsstörungen und aufmerksamkeits- /hyperaktivitätsstörungen mit methylphenidat
ATE455106T1 (de) Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
ATE286028T1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE60032910D1 (de) Mittel zum nachweis und zur behandlung von krankheiten die in verbindung stehen mit fgfr3
DE60223715D1 (de) Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DE60226702D1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
ATE319453T1 (de) Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DE60032823D1 (de) Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE60233265D1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
PT1212317E (pt) Derivados de indole e sua utilizacao no tratamento de osteoporose entre outras aplicacoes
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
DE60017133D1 (de) Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
NO20030295D0 (no) Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60001725D1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
DE69733479D1 (de) Verfahren zum screenen auf elizitären, die die phytroalexinproduktion in reis induzieren und mittel zur bekämpfung von reiskrankheiten, die einen solchen elizitor als wirkstoff enthalten
ATE247466T1 (de) Pharmazeutische zubereitungen enthaltend ibuprofen und domperidon zur behandlung von migräne

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings